About Index Trending news
Analyze
Pricing
Merck

Merck

Merck

Merck's official Twitter handle. Intended for US residents only. Tweeting about our commitment to saving & improving lives.

Elsewhere

Contributors to this profile

Alexa global traffic share

Twitter followers

Employees

Team size

10000+
Locations
HQ
Headquarters
Xconomy

In a Myeloma Setback, Merck Halts Studies Due to Patient Deaths

TechMoran

Tunisia, a new frontier for African startups as Merck plan to launch e-health incubation in the country

Funding Technology Global
Xconomy

Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer

TechMoran

Merck Accelerator announces 3 startups to join its program in Nairobi

Xconomy

Merck Alzheimer Drug Is Latest To Fail In A Big Study

TechCrunch , Bloomberg

With billions of dollars at stake, Merck and Palantir partner to discover drugs faster

Health Funding
Xconomy

Vertex Deals Cancer Drugs to Merck for $230M, Staying True to Plan

Xconomy , New York Times Bits

Merck Surges As Bristol’s Immunotherapy Drug Stumbles in Lung Cancer

Health Earnings
Xconomy

Merck, Amgen Invest in Akili as Therapeutic Video Game Moves Ahead

Health Funding
Xconomy

Moderna Gets $200M More, Deepens Merck Ties With New Cancer Pact

Health Funding
The Motley Fool

Attention Merck Investors: It's Time to Start Worrying

Xconomy

Gerngross Mulls Buying Back GlycoFi After Merck Closes HQ

The Motley Fool

5 Surprising Comments in Merck's Quarterly Conference Call

The Motley Fool

Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut

The Motley Fool

5 Data Points Wall Street Is Anxiously Awaiting in Merck's Q1 Report

Health Earnings
The Motley Fool

16 Reasons to Buy Merck and Never Sell

Health Stock markets
The Motley Fool

Patent Payoff? Merck's and Ionis Pharmaceuticals' Take Could Be Tiny

The Motley Fool

The Surprising Winner in Merck's Patent War With Gilead Sciences

Xconomy

Tech Megatransfer: Merck Pays Harvard $20M For "Accelerated" Cancer Drugs

The Motley Fool

Better Buy: Pfizer Inc. vs. Merck

Stock markets Earnings Health